Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Change in Account Payables (2016 - 2025)

Heron Therapeutics (HRTX) has disclosed Change in Account Payables for 14 consecutive years, with -$3.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Account Payables fell 298.75% year-over-year to -$3.0 million, compared with a TTM value of -$2.7 million through Dec 2025, down 132.06%, and an annual FY2025 reading of -$2.7 million, down 132.06% over the prior year.
  • Change in Account Payables was -$3.0 million for Q4 2025 at Heron Therapeutics, down from -$20000.0 in the prior quarter.
  • Across five years, Change in Account Payables topped out at $9.6 million in Q2 2021 and bottomed at -$7.3 million in Q3 2022.
  • Average Change in Account Payables over 5 years is $423450.0, with a median of -$29000.0 recorded in 2024.
  • Peak annual rise in Change in Account Payables hit 545.4% in 2024, while the deepest fall reached 386.07% in 2024.
  • Year by year, Change in Account Payables stood at -$2.1 million in 2021, then plummeted by 59.56% to -$3.3 million in 2022, then skyrocketed by 141.54% to $1.4 million in 2023, then increased by 10.22% to $1.5 million in 2024, then tumbled by 298.75% to -$3.0 million in 2025.
  • Business Quant data shows Change in Account Payables for HRTX at -$3.0 million in Q4 2025, -$20000.0 in Q3 2025, and -$296000.0 in Q2 2025.